Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, representing a 2% year-over-year increase, with a 7% growth in non-respiratory revenue excluding donor screening [7][18] - Full year revenue reached $2.73 billion, achieving the company's financial guidance for 2025, with non-respiratory revenue growing 5% [7][18] - Adjusted EBITDA margin was 22%, reflecting a 240 basis point improvement over the prior year [8][22] - Adjusted diluted EPS was $0.46 in Q4 and $2.12 for the full year, indicating a 15% year-over-year growth [22] Business Line Data and Key Metrics Changes - Labs business reported a strong growth of 7% in Q4 and 6% for the full year, accounting for 55% of total company revenue [7][18] - Immunohematology business grew 3% for the full year, maintaining its leading global market position [18] - Triage business saw a revenue increase of 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [20] - Europe, Middle East, and Africa showed flat growth for the quarter and 4% growth for the year, with a significant increase in Adjusted EBITDA margins by over 900 basis points [20] - Latin America experienced a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [20] - China grew 5% in Q4 and 3% for the full year [21] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [6] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [35] - The company anticipates continued growth in the Labs business and is optimistic about new product launches in 2026 [14][25] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow metrics [31][88] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [8][22] - Joe Busky, CFO, announced his retirement effective June 2026, with a search for his successor already initiated [9][10] Q&A Session Summary Question: Free cash flow guidance and timing issues - Joe Busky explained that Q4 cash flow was lower than expected due to timing issues with accounts receivable and late revenue collection [30][31] Question: Sustainability of lab growth trends - Brian Blaser highlighted strong underlying growth rates across the business and emphasized opportunities in immunoassay and low market penetration [33][35] Question: China market updates - Management provided updates on potential nationalized value-based procurement programs but noted no new developments [40][41] Question: Gross margin performance - Joe Busky discussed factors affecting gross margins, including tariffs and product mix, and projected flat margins for 2026 [67][68] Question: Lex Diagnostics platform timeline - Jonathan Siegrist confirmed that the FDA review process for the Lex platform is progressing as planned, with no current issues [72] Question: R&D pipeline and product launches - Management indicated a focus on expanding the product portfolio and enhancing offerings in both domestic and international markets [76][78]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, representing a 2% year-over-year increase from $708 million, with a 7% growth in non-respiratory revenue excluding donor screening [7][18] - Full year revenue reached $2.73 billion, achieving the 2025 financial guidance, with non-respiratory revenue growing 5% [7][18] - Adjusted EBITDA margin was 22%, a 240 basis point improvement over the prior year [8][22] - Adjusted diluted EPS was $0.46 for Q4 and $2.12 for the full year, reflecting a 15% year-over-year growth [22] Business Line Data and Key Metrics Changes - Labs business reported a 7% growth in Q4 and 6% for the full year, representing 55% of total company revenue [7][18] - Immunohematology grew 3% for the full year, maintaining its leading global market position [18] - Triage business revenue increased by 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined by 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [20] - Europe, Middle East, and Africa (EMEA) growth was flat in Q4 and up 4% for the year, with adjusted EBITDA margins increasing by over 900 basis points [20] - Latin America saw a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [20] - China grew 5% in Q4 and 3% for the full year [21] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [6][9] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [35] - The company anticipates continued growth in the Labs business and is optimistic about new product launches in 2026 [14][25] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow metrics [31][89] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [22] - The CFO announced plans to retire in June, with a search for a successor already initiated [9][10] Q&A Session Summary Question: Free cash flow guidance and timing issues - The CFO explained that Q4 cash flow was lower than expected due to timing issues with accounts receivable and late revenue collection [30][31] Question: Sustainability of Labs business growth - Management highlighted strong underlying growth rates and opportunities in immunoassay and underpenetrated markets as key factors for sustaining growth [35] Question: Updates on China market and VBP program - Management stated that there are no new updates on the nationalized VBP program for dry chemistry test strips, with potential impacts estimated at 0.5% to 1% of total revenue [40][41] Question: Gross margin outlook - The CFO discussed factors affecting gross margins, including tariffs and product mix, and projected flat gross margins for 2026 with potential improvements in the following years [68][70] Question: LEX Diagnostics platform timeline - Management indicated that the FDA review process for the LEX platform is progressing as planned, with no current issues [73] Question: R&D pipeline and U.S. market focus - Management confirmed that while OUS markets are a priority, there are plans to enhance the U.S. product offerings through new menu additions [77][79]

Financial Data and Key Metrics Changes - Fourth quarter revenue was $724 million, a 2% increase from $708 million in the prior year, with a 7% growth in non-respiratory revenue excluding donor screening [6][18] - Full year revenue reached $2.73 billion, achieving the 2025 financial guidance, with non-respiratory revenue growing 5% [6][18] - Adjusted EBITDA margin was 22%, reflecting a 240 basis point improvement year-over-year [8][21] - Adjusted diluted EPS was $0.46 for Q4 and $2.12 for the full year, representing a 15% year-over-year growth [21] Business Line Data and Key Metrics Changes - Labs business reported a strong growth of 7% in Q4 and 6% for the full year, representing 55% of total company revenue [6][18] - Immunohematology grew 3% for the full year, maintaining its leading global market position [18] - Triage business revenue increased by 16% in Q4 and 7% for the full year [18] - Respiratory revenue declined by 14% in Q4 and 20% for the full year due to lower COVID testing [18] Market Data and Key Metrics Changes - North America region revenue was up 4% in Q4 but down 2% for the year, excluding donor screening [19] - Europe, Middle East, and Africa (EMEA) growth was flat for the quarter and up 4% for the year, with a significant increase in Adjusted EBITDA margins by over 900 basis points [19] - Latin America saw a 17% increase in Q4 and 18% for the year, while Japan and Asia-Pacific grew 4% in Q4 and 6% for the year [19] - China grew 5% in Q4 and 3% for the full year [19] Company Strategy and Development Direction - The company established three priorities: customer-centric operations, strengthening operational and financial performance, and accelerating product development for long-term growth [5] - The focus is on optimizing the customer experience and driving effective execution across all business dimensions [9] - The company aims to maximize value by delivering superior outcomes for customers and converting that value into attractive returns for shareholders [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain growth, citing strong market positions and high renewal rates [34] - The company anticipates continued growth in the Labs business and expects to launch new products in 2026, including the VITROS 450 platform [14][15] - Management acknowledged challenges in cash flow conversion but emphasized ongoing efforts to improve cash flow and margin performance [88] Other Important Information - A significant non-cash goodwill impairment charge of $701 million was recorded in Q3, which does not impact cash or operations [21] - The CFO announced plans to retire in June, with a search for a successor already initiated [9] Q&A Session Summary Question: Free cash flow guidance and timing of cash collections - Management explained that Q4 cash flow was lower than expected due to timing issues with cash collections, with $45 million expected to be collected in Q4 but realized in January [30][31] Question: Sustainability of lab growth trends - Management expressed optimism about sustaining growth, highlighting strong market positions and opportunities in immunoassay and low market penetration [34] Question: Updates on China and dry slide procurement - Management stated there were no new updates regarding the nationalized VBP program for dry chemistry test strips in China, with potential impacts estimated at 0.5% to 1% of total revenue [40] Question: Margins and direct procurement initiatives - Management indicated that direct procurement initiatives are expected to improve margins over time, with a goal of reaching closer to 50% gross margin in the coming years [68][69]